Protective Effects of Melatonin Against the Damages of Neuroendocrine-immune Induced by Lipopolysaccharide in Diabetic Rats

 

 Buy Article Permissions and Reprints

Abstract

The present study was to determine the protective effects of melatonin (MLT) against the damages of neuroendocrine-immune induced by lipopolysaccharide (LPS) in streptozotocin (STZ)-induced diabetic rats, and to analyze the parameters related to diabetes and oxidative stress. A total of 70 male Sprague-Dawley rats were assigned to this experiment. 10 of rats received STZ intraperitoneally (i.p.) alone as diabetic control; 40 of rats as the Diabetes+LPS received STZ plus LPS i.p. after induction of diabetes with STZ, then assigned to sub-groups as MLT_0.1 mg, MLT_1 mg, and Vehicle group, received two doses MLT and vehicle, i.p., respectively, q6 h for 12 h after LPS administration; and the remaining served as normal and LPS control. LPS significantly increased the serum levels of TNF-α and IL-6 in normal and diabetic rats; LPS also dramatically increased the plasma concentrations of corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH), and corticosterone. Both 0.1 and 1 mg/kg MLT doses significantly decreased the serum levels of TNF-α and IL-6. Significant inhibitory effects of MLT (1 mg/kg) were observed on the plasma concentrations of CRH, ACTH, and corticosterone of the HPA axis. The beneficial effects of MLT, such as the antioxidant activity and maintaining glucose homoeostasis, were also observed in this study, this resulted in a protective effect against the damages caused by LPS in STZ-induced diabetic rats. This finding probably provides a new approach for preventing the undesirable effects of the vicious cycle of hyperglycemia and stress factors such as severe infection in diabetic patients.

References

• 1 Araya AV, Pavez V, Perez C. et al . Ex vivo lipopolysaccharide (LPS)-induced TNF-alpha, IL-1beta, IL-6 and PGE₂secretion in whole blood from Type 1 diabetes mellitus patients with or without aggressive periodontitis.  Eur Cytokine Netw. 2003;  14 128-133
  PubMedGoogle Scholar
• 2 Borjigin J, Li XD, Snyder SH. et al . The pineal gland and melatonin:molecular and pharmacologic regulation.  Ann Rev Pharmacol Toxicol. 1999;  39 53-65
  CrossrefPubMedGoogle Scholar
• 3 Bellipanni G, Bianchi P, Pierpaoli W. et al . Effects of melatonin in per-menopausal and menopausal women: a randomized and placebo controlled study.  Exp Gerontol. 2001;  36 297-310
  CrossrefPubMedGoogle Scholar
• 4 Chan O, Inouye K, Vranic M. et al . Hyperactivation of the hypothalamo-pituitary-adrenocortical axis in streptozotocin-diabetes is associated with reduced stress responsiveness and decreased pituitary and adrenal sensitivity.  Endocrinology. 2002;  143 1761-1768
  CrossrefPubMedGoogle Scholar
• 5 Chan O, Inouye K, Riddell MC. et al . Diabetes and the hypothalamo-pituitary-adrenal (HPA) axis.  Minerva Endocrinolpgica. 2003;  28 87-102
  PubMedGoogle Scholar
• 6 Cam M, Yavuz O, Guven A. et al . Protective effects of chronic melatonin treatment against renal injury in streptozotocin-induced diabetic rats.  J Pineal Res. 2003;  35 212-220
  CrossrefPubMedGoogle Scholar
• 7 Defrance R, Quera-Salva MA. Therapeutic applications of melatonin and related compounds.  Hormone Research. 1998;  49 142-146
  CrossrefPubMedGoogle Scholar
• 8 Derlacz RA, Sliwinska M, Piekutowska A. et al . Melatonin is more effective than taurine and 5-hydroxytryptophan against hyperglycemia-induced kidney-cortex tubules injury.  J Pineal Res. 2007;  42 203-209
  CrossrefPubMedGoogle Scholar
• 9 Turek FW. Circadian rhythms.  Horm Res. 1998;  49 109-113
  CrossrefPubMedGoogle Scholar
• 10 Geoffriau M, Brun J, Chazot G. et al . The physiology and pharmacology of melatonin in humans.  Hormone Research. 1998;  49 136-141
  CrossrefPubMedGoogle Scholar
• 11 Gohil BC, Rosenblum LA, Coplan JD. et al . Hypothalamic-pituitary-adrenal axis function and the metabolic syndrome X of obesity.  CNS Spectrums. 2001;  6 581-589
  PubMedGoogle Scholar
• 12 Gorgun FM, Kokoglu E, Gumustas MK. et al . Effects of melatonin on plasma S-nitrosoglutathione and glutathione in streptozotocin-treated rats.  Journal of Toxicology and Environmental Health. Part A. 2004;  67 979-986
  CrossrefPubMedGoogle Scholar
• 13 Konakchieva R, Mitev Y, Almeiga OF. et al . Chronic melatonin treatment and the hypothalamus-pituitary axis in the rat: attenuation of the secretary response to stress and effects on hypothalamic neuropeptide content and release.  Biology Cell. 1997;  89 587-596
  PubMedGoogle Scholar
• 14 Konakchieva R, Mitev Y, Almeiga OF. et al . Chronic melatonin treatment counteracts glucocorticoid-induced dysregulation of the hypothalamic-pituitary-adrenal axis in the rat.  Neuroendocrinology. 1998;  67 171-180
  CrossrefPubMedGoogle Scholar
• 15 Kostoglou-Athanassiou I, Treachert DF, Wheeler MJ. et al . Melatonin administration and pituitary hormone secretion.  Clinical Endocrinology. 1998;  48 31-37
  CrossrefPubMedGoogle Scholar
• 16 Kurcer Z, Parlakpinar H, Vardi N. et al . Protective effects of chronic melatonin treatment against renal ischemia/reperfusion injury in streptozotocin-induced diabetic rats.  Exp Clin Endocrinol Diabetes. 2007;  115 365-371
  Article in Thieme ConnectPubMedGoogle Scholar
• 17 Kanter M, Uysal H, Karaca T. et al . Depression of glucose levels and partial restoration of pancreatic beta-cell damage by melatonin in streptozotocin-induced diabetic rats.  Arch Toxicol. 2006;  80 362-369
  CrossrefPubMedGoogle Scholar
• 18 Luboshitzky R. Endocrine activity during sleep.  J Pediatr Endocrinol Metab. 2000;  13 13-20
  PubMedGoogle Scholar
• 19 Oktem F, Ozguner F, Yilmaz HR. et al . Melatonin reduces urinary excretion of N-acetyl-beta-D-glucosaminidase, albumin and renal oxidative markers in diabetic rats.  Clin and Exp Pharmacol & Physiol. 2006;  33 95-101
  PubMedGoogle Scholar
• 20 Pickup JC, Chusney GD, Thomas SM. et al . Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes.  Life Sciences. 2000;  67 291-300
  CrossrefPubMedGoogle Scholar
• 21 Ran RQ, Lu AG, Zhang L. et al . Hsp70 promotes TNF-mediated apoptosis by binding IKK γ and impairing NF-kB survival signaling.  Gene Develop. 2004;  18 1466-1481
  CrossrefPubMedGoogle Scholar
• 22 Sacco S, Aquilini L, Ghezzi P. et al . Mechanism of the inhibitory effect of melatonin on tumor necrosis factor production in vivo and in vitro.  Eur J Pharmacol. 1998;  343 249-255
  CrossrefPubMedGoogle Scholar
• 23 Soop M, Duxbury H, Agwunobi AO. et al . Euglycemic hyperinsulinemia augments the cytokine and endocrine responses to endotoxin in humans.  Am J Physiol Endocrinol Metab. 2002;  282 E1276-1285
  PubMedGoogle Scholar
• 24 Sudnikovich EJ, Maksimchik YZ, Zabrodskaya SV. et al . Melatonin attenuates metabolic disorders due to streptozotocin-induced diabetes in rats.  Eur J Pharmacol. 2007;  569 180-187
  CrossrefPubMedGoogle Scholar
• 25 Wehr TA. Effect of seasonal changes in daylength on human neuroendocrine function.  Horm Res. 1998;  49 118-124
  CrossrefPubMedGoogle Scholar
• 26 Winiarska K, Fraczyk T, Malinska D. et al . Melatonin attenuates diabetes-induced oxidative stress in rabbits.  J Pin Res. 2006;  40 168-176
  PubMedGoogle Scholar
• 27 Yavuz O, Cam M, Bukan N. et al . Protective effect of melatonin on beta-cell damage in streptozotocin-induced diabetes in rats.  Acta Histochemistry. 2003;  105 261-266
  PubMedGoogle Scholar
• 28 Zhong LY, Jin H, Gao F. et al . Exogenous melatonin inhibited the function of pituitary-adrenal in alloxan-induced diabetic rats.  Chin J of Endocrinol Metab. 2003;  19 141-143
  PubMedGoogle Scholar

Correspondence

L.-Y. Zhong

Department of Endocrinology

Beijing Tiantan Hospital

Capital Medical University

No.6 Tiantan Xili Road

Chongwen District

100050 Beijing

China

Phone: +86/10/670 966 18

Fax: +86/10/670 360 38

Email: zhongliyong@126.com